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Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, 
nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity 
of the drug and to reduce its side toxic effects. Aim: To estimate the antitumor effects of С60-Cis-Pt nanocomplex in Lewis lung 
carcinoma (LLC) and analyze hematological toxicity in tumor-bearing mice. Materials and Methods: Complexation of C60 fullerene 
and Cis-Pt molecule was studied by computer simulation. С60-Cis-Pt nanocomplex was i.p. injected to LLC-bearing mice in a total 
dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/kg). The survival of tumor-bearing mice and the relative reduction of tumor weight 
was recorded. Blood indices were determined using the Particle Counter PCE 210 automatic hematology analyzer. Results: Computer 
simulation demonstrated the formation of С60-Cis-Pt nanocomplex in physiological medium and its stability due to the hydrophobic 
interactions. Treatment with C60-Cis-Pt nanocomplex increased survival time of LLC-bearing mice by 32%, normalized hemoglobin 
content (up to 100 g/l), erythrocyte and platelet count as compared to the untreated LLC-bearing mice. Tumor weight decreased 
by 35.5%; the mitotic index of tumor cells decreased by 78%, and apoptotic index increased by 75%. The revealed effects of the 
C60-Cis-Pt nanocomplex were more pronounced than the effects of Cis-Pt or C60 fullerene alone in equivalent dose. Conclusion: 
Treatment with C60-Cis-Pt nanocomplex prolonged the survival of LLC-bearing mice and reduced anemia in LLC-bearing mice.
Key Words: cisplatin, C60 fullerene, С60-Cis-Pt nanocomplex, Lewis lung carcinoma, tumor-bearing mice survival, hematological 
indices.
Cisplatin (Cis-[Pt(II)(NH3)2Cl2, Cis-Pt) is a metal-con-
taining alkylating drug that is widely used to treat a num-
ber of cancers. Therapeutic efficiency of Cis-Pt is lim-
ited by high toxicity, non-selective distribution of the 
drug between normal and tumor tissues and develop-
ment of drug resistance [1]. In order to overcome these 
limitations, nanoparticles have been used as drug 
delivery and carrier systems in order to promote prefe-
rential accumulation in cancer cells and thereby reduce 
adverse side effects. Recent studies have shown that 
combination or conjunction of anticancer drug with 
nanoparticles could enhance its permeability and reten-
tion effect, as well as provide selective accumulation 
in tumor cells [2, 3].
A variety of carriers, organic (biopolymers, poly-
meric conjugates, micelles and liposomes) and inor-
ganic (carbon, iron oxide, gold and silica) nanoparticles 
have been used to modify the action of platinum-based 
drugs [4]. Cis-Pt conjugated with gold-coated iron 
oxide nanoparticles (Pt@Au@FeNPs) was more toxic 
towards Cis-Pt-sensitive and resistant human ovarian 
carcinoma A2780 cells than the free drug [5]. Cis-Pt 
(Pt IV) conjugated with PEGylated gold nanorods was 
more toxic against Cis-Pt-sensitive and resistant lung 
cancer A549 cells and facilitated drug uptake through 
endocytosis in comparison with the free drug [6].
The ability of carbon nanoparticles to modulate an-
titumor activity of Cis-Pt was shown. So, single-walled 
carbon nanotubes could be promising for targeted drug 
delivery [7], metallofullerenes with gadolinium [Gd@
C82(OH)22]n overcome tumor resistance to Cis-Pt by re-
activating the impaired endocytosis of Cis-Pt-resistant 
human prostate cancer (CP-r) cells [8], an increased 
cytotoxic effect of Cis-Pt in combination with fullerenol 
against HeLa and Lewis lung carcinoma (LLC) cells was 
demonstrated [9, 10].
C60 fullerene, being a representative of carbon 
nanostructures, can be a promising agent for anti-
cancer drug delivery. C60 fullerene is a chemically 
stable molecule, able to penetrate biological mem-
branes. It localizes in normal cells without toxic ef-
fects in a range of 10-7–10-5 M and exhibits powerful 
antioxidant properties [11–17]. A selective accumu-
lation of C60 fullerene nanoparticles in tumor tissue 
was demonstrated [18–20]. The unique structure 
of C60 molecule makes it possible to modify its sur-
face with chemotherapeutic agents [21–23]. It was 
de monstrated that C60 fullerene conjugated with pa-
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clitaxel or doxorubicin exhibited increased antitumor 
activity as compared with free drugs [24–26].
The aim of this study was to estimate the antitumor 
effects of С60-Cis-Pt nanocomplex in LLC and analyze 
its hematotoxicity in tumor-bearing mice.
MATERIALS AND METHODS
C60-Cis-Pt nanocomplex. A highly stable pristine 
C60 fullerene aqueous colloid solution (C60FAS; final 
concentration 0.15 mg/ml, purity > 99.5%) was ob-
tained at Technical University of Ilmenau (Germany) 
as discribed in [27, 28]. In brief, this method is based 
on transferring C60 fullerene from organic solution 
into the aqueous phase by ultrasonic treatment. The 
monitoring of the state of C60 fullerene nanopar-
ticles in aqueous solution using microscopic and 
spectroscopic measurements showed the pre sence 
of both single C60 molecules and their nanoaggre-
gates with the size in the range of 1.2–100 nm. The 
C60FAS was stable for 6–8 months at room tempera-
ture [29]. To obtaine C60-Cis-Pt nanocomplex C60FAS 
(150 µg/ml) and Cis-Pt dissolved in 0.9% NaCl saline 
solution (150 µg/ml) were mixed in 1:1 volume ratio 
(C60:Cis-Pt molar ratio 1:2.4). This mixture was treated 
by ultrasound (22 kHz, 20 min) with further stirring 
on the magnetic stirrer (400 rpm, 18 h). The final con-
centrations of С60 fullerene and Cis-Pt in the obtained 
nanocomplex were 75 and 75 µg/ml, respectively.
In silico experiment. Structures of C60 fullerene 
and Cis-Pt molecule, as well as the 1:1 C60-Cis-Pt nano-
complex were characterized according to the procedure 
described in [30]. The energy minimization of the complex 
in the water environment was accomplished in X-PLOR 
software (1423 TIP3P water molecules in cubic box) by the 
method of molecular mechanics with CHARMM27 force 
field. The resultant 1:1 C60-Cis-Pt structure was further 
used to populate the surface of C60 fullerene by several 
Cis-Pt molecules in a way, which creates sterical condi-
tions for the contact between neighbouring Cis-Pt mol-
ecules via hydrogen bonds. Further execution of energy 
minimization procedure allowed testifying the stability 
of such nanocomplex at each iteration by changing the 
number of bound Cis-Pt molecules. Such approach en-
abled to estimate the maximal number of drug molecules, 
which may bind with C60 fullerene.
In vivo experiments
Animals. Studies were carried out on the male 
С57Вl/6 mice 2–2.5 months old weighing 22–
24 g from the vivarium of the R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy (IEPOR) оf the NAS of Ukraine, Kyiv, Ukraine. All 
experiments were conducted in accordance with the 
international regulations of the European Convention 
for protection of vertebrate animals under control 
of the Bio-Ethical Committee of the NAS of Ukraine.
Tumor model. National Bank of Cell Lines and 
Transplanted Tumors of R.E. Kavetsky IEPOR of the NAS 
of Ukraine kindly provided LLC cells. LLC cells (5•105) 
were transplanted into the limb by intramuscular injection.
Design of the experiment. Treatment (5 consecutive 
days with 1-day interval) started on the 2nd day after tu-
mor transplantation. LLC-bearing mice were rando mized 
by weight and divided into 4 groups with 20 animals per 
group (12 mice for survival and 8 mice for haematologi-
cal and histological parameters study): untreated mice 
(0.9% NaCl saline solution); C60 fulle rene group (C60FAS); 
Cis-Pt group (Cis-Pt in 0.9% NaCl saline solution); C60-
Cis-Pt nanocomplex group (C60-Cis-Pt nanocomplex 
solution). The intact group (0.9% NaCl saline solution) 
consisted of healthy mice without transplanted tumor. 
C60 fullerene (in a total dose of 3.75 mg/kg), Cis-Pt 
(in a total dose of 3.75 mg/kg), C60-Cis-Pt nanocomplex 
(in a total dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/
kg)) were injected intraperitoneally (i.p.).
An average lifespan (LS, days) of mice in each 
group, a coefficient of animal life prolongation (cp, 
% relative to the untreated tumor-bearing mice) and 
survival of tumor-bearing mice (%) in each group du-
ring the experiment were calculated.
Hematological analysis. The blood was collected 
from the tail vein into the tube with K3EDTA anticoa-
gulant (C-Sanguis Counting Kotrollblutherstellungs-und 
Vertriebs GmbH, Germany) on the 22nd day after trans-
plantation of LLC. Determination of hematological indices 
in blood was performed using automatic hematology 
analyzer Particle Counter PCE-210 (ERMA Inc., Japan).
Antitumor activity. Autopsy was carried out im-
mediately after euthanasia with CO2 on the 22nd day 
after LLC transplantation. The inhibitory rate (IR, %) 
of the tumor was calculated as follows
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where twc and twt is average tumor weight (g) in un-
treated tumor-bearing animals (c) and treatment (t) 
groups of animals, respectively.
Histological study. Tumors were excised and fixed 
in 10% neutral buffered formalin, and then subjected 
to standard histological processing and staining with 
hematoxylin and eosin (HE). Slides were analyzed using 
a light microscope Olympus BX-41 (Olympus Europe 
GmbH, Japan) and camera Olympus C-5050 Zoom 
(Olympus Europe GmbH, Japan). Slides were screened 
for apoptosis and mitosis. Apoptotic index was calcu-
lated as the number of apoptotic cells and apoptotic 
bodies. Mitotic index was calculated by counting mitosis 
among 1000 cells. Apoptotic and mitotic indices were 
expressed as percentage of total cell number.
Statistical analysis. All statistical analyses were 
performed with the Origin 8.0 software (OriginLab Cor-
poration, USA). Student’s test was used to compare 
groups with p < 0.05 being considered significant.
RESULTS AND DISCUSSION
Computer simulation. Results of the structural 
modeling of С60-Cis-Pt nanocomplex in the 1:1 ratio 
of C60 fullerene and Cis-Pt molecule (Fig. 1, a) evi-
denced the stability of this structure in aqueous me-
dia. The minimal distance between С60 fullerene and 
Cis-Pt molecule was found to be 2.75 Å indicating the 
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importance of dispersive van der Waals attractive in-
teractions between Pt atom and aromatic C60 fullerene 
surface in stabilization of the nanocomplex.
The energy-minimized structure with the theo-
retically maximal filling of the C60 fullerene surface 
with Cis-Pt molecules is shown in Fig. 1, b. The data 
obtained evidenced the possibility of the binding 
of fifteen Cis-Pt molecules with C60 fullerene. The 
planes of cruciform Cis-Pt molecules were parallel 
to the planes tangent to the surface of C60 fullerene. 
No preferential arrangement of Cis-Pt molecules 
over the five- or six-membered C60 fullerene rings 
was shown. Apparently, this is determined by the lack 
of aromatic ring in Cis-Pt molecule and the absence 
of a classical π-stacking with the C60 fullerene. Nu-
merical calculations showed that the total binding 
energy of Cis-Pt molecules with C60 fullerene is about 
–8.6 kcal/mol and the main contribution to the stabili-
zation of the nanocomplex is made by the hydrophobic 
interactions. Electrostatic interactions both between 
molecules in the nanocomplex and with water mole-
cules were very weak due to the electroneutrality 
of both molecules and the non-polarity of C60 fullerene.
The in silico results point out on interaction 
of C60 fullerene and Cis-Pt molecules and stability 
of С60-Cis-Pt nanocomplex in physiological media under 
the conditions of in vivo experiment. This fact should 
be taken into consideration when interpreting biologi-
cal data with these  compounds used in combination.
Finally, it is important to note that using various 
physico-chemical methods, including the small-angle 
neutron scattering, scanning and atomic force micro-
scopies, dynamic light scattering and UV-Vis spec-
troscopy as well as the isothermal titration calorimetry, 
it was shown that Cis-Pt molecules could be adsorbed 
on the surface of single С60 fullerene or its nanocluster 
resulting in formation of noncovalent C60-Cis-Pt nano-
complex stabilized by hydrophobic interactions [23].
The survival of LLC-bearing mice treated 
with Cis-Pt and C 60 fullerene separately 
or with C60-Cis-Pt nanocomplex. Antitumor activity 
of Cis-Pt was investigated in the range of high concen-
trations, mainly more than 10 mg/kg body weight of the 
animal [31], but significant toxicity of the drug and high 
lethal effect complicate the long-term evaluation of its 
antitumor activity. We used the model of multiple i.p. 
injections of Cis-Pt in a total dose of 3.75 mg/kg and 
C60-Cis-Pt nanocomplex in a total dose of 7.5 mg/kg 
(C60:Cis-Pt as 3.75:3.75 mg/kg).
Recent studies have shown that metalofullerene 
Gd@C82(ОН)22 under i.p. administration of 3.8 mg/kg 
(once a day for 7 days) did not cause pronounced side 
effects in mice with transplantated human breast can-
cer MCF-7 cells, none of animals died, the body weight 
of animals corresponded to normal values, while 
animal lethality was observed in the untreated group 
and in the group that received paclitaxel in a dose 
of 10 mg/kg (4 times each 3 days) [32].
In our study, the average survival of untreated 
tumor-bearing mice was 25 days. Survival and average 
LS of LLC-bearing mice treated with Cis-Pt, C60 fulle-
rene, or С60-Cis-Pt nanocomplex increased as com-
pared to control, with the average survival of 31, 29, 
and 33 days, respectively (Fig. 2, Table 1). It is worth 
noting that the survival prolongation of tumor-trans-
planted mice by 25% and more in groups under the 
effect of drugs compared to untreated group is con-
sidered to be an effective antitumor response [33].
Table 1. Average LS and coefficient of life prolongation (cp) of LLC-bear-
ing mice treated with either Cis-Pt and С60 fullerene separately or with 
С60-Cis-Pt nanocomplex
Experimental groups LS, days cp, %
Untreated 25 ± 2 –
+ Cis-Pt 31 ± 3 24 ± 4*
+ С60 fullerene 29 ± 2 16 ± 4
+ С60-Cis-Pt nanocomplex 33 ± 3* 32 ± 5*
Note: *p < 0.05 as compared to tumor-bearing mice treated with saline.
The prolongation of the survival in LLC-bearing mice 
in experimental groups evidences the effective antitu-
mor action of Cis-Pt both separately and at complexation 
with C60 fullerene (Table 1). С60-Cis-Pt nanocomplex was 
observed to perform the most potent antitumor effect, 
as coefficient of animal life prolongation in this group 
of tumor-bearing animals was higher compared to the 
one exposed to separate administration of Cis-Pt and 
C60 fullerene by 1.3 and 2 times, respectively.
Our results are in a good agreement with the data 
presented in [34], where a 2-fold prolongation of Dal-
ton’s ascites lymphoma-transplanted mice survival 
time under the action of Cis-Pt was shown as com-
pared with untreated group.
                       a                                                         b
Fig. 1. The calculated structure of 1:1 (a) and 1:15 (b) 
С60-Cis-Pt nanocomplexes
Fig. 2. Survival (%) of LLC-bearing mice treated with either 
Cis-Pt and C60 fullerene separately or with C60-Cis-Pt nanocomplex
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Hematological toxicity in LLC-bearing 
mice treated with Cis-Pt, C60 fullerene or with 
C60-Cis-Pt nanocomplex. Results of blood analysis 
on the 22nd day after LLC transplantation to mice are 
presented in Table 2. The decrease in hemoglobin 
content (by 11%) and hematocrit (by 21%) as well 
as a decrease in the count of erythrocytes by 38%, 
lymphocytes by 30%, and thrombocytes by 30% on the 
22th day after tumor transplantation as compared to the 
corresponding indices in intact animals evidenced 
anemia development in tumor-bearing mice. 1.4-fold 
increase in leukocyte count indicated leukocytosis 
as tumor-associated inflammatory process (Table 2). 
Earlier, the leukemoid reaction with a significant in-
crease of monocyte count was demonstrated in ani-
mals with highly angiogenic LLC [35].
Antitumor drugs are known to suppress hema-
topoiesis. Cis-Pt caused hematotoxicity at both low 
(10-8–10-12 g/ml per rat) [36] and high (4–16 mg/kg) 
concentrations [34, 37–39], with the development 
of anemic conditions both in intact and tumor-
bearing animals. In our study, Cis-Pt in a total dose 
of 3.75 mg/kg aggravated anemia in LLC-bearing 
mice as evidenced by the reduction of hemoglobin 
and erythrocyte levels by 21% and 20%, respectively, 
and lymphocytopenia (Table 2).
In order to prevent anemic conditions during and after 
chemotherapy, antioxidants have become widely used 
in a medical practice. The side effects of chemotherapy, 
in particular, Cis-Pt-induced anemia in tumor-bearing 
animals, were prevented by combined treatment with 
antioxidants, such as selenium Se and ascorbic acid 
[34, 39]. The powerful antioxidant properties of pristine 
water-soluble C60 fullerene were confirmed in vitro and 
in vivo experiments [40–43]. We have previously shown 
that C60 fullerene protected thymocytes from the dam-
age induced by 100 µM hydrogen peroxide or Cis-Pt 
(3.3 and 16.7 µM). After the treatment of cells with 
10–5 M C60 fullerene the increased reactive oxygen species 
level induced by H2O2 or Cis-Pt in thymocytes was norma-
lized and erythrocytes hemolysis induced by Cis-Pt was 
prevented [12, 41, 43]. In addition, it was demonstrated 
that C60 fullerene prevented Dox-dependent oxidative 
insults in LLC-bearing mice liver and heart [42]. In present 
study, C60 fullerene reduced anemia in LLC-bearing mice 
(Table 2) with hematologic indices approaching those 
in intact animals. C60-Cis-Pt nanocomplex reduced the 
hematotoxicity in tumor-bearing mice caused by tumor 
growth and drug treatment. These finding are of some 
interest taking into account the systemic effects of the 
tumor on the host and the development of paraneoplastic 
syndrome [45].
Antitumor effects of Cis-Pt, C60 fullerene 
or C60-Cis-Pt nanocomplex. The inhibitory effect 
on tumor growth was evident in all treated groups. 
Treatment of LLC-bearing mice with Cis-Pt or C60 fuller-
ene was accompanied by 1.36 and 1.23-fold decrease 
of tumor weight with 26.3 and 18.4% IR, respectively, 
in comparison with untreated group, while treatment 
with C60-Cis-Pt nanocomplex was accompanied 
by 1.55-fold decrease of tumor weight with 35.5% IR 
(Table 3). Earlier, we have shown that antimetaststic 
effects of C60-Cis-Pt nanocomplex exceed those 
of Cis-Pt (75% vs 57% of total metastases volume 
reduction) [46]. The data on antitumor effects 
of C60-Cis-Pt nanocomplex and decreasing hema-
tological toxicity as compared to the free drug are 
consistent with antimetastatic effects of this complex.
Table 3. Tumor weights and tumor IR in LLC-bearing mice treated with 
either Cis-Pt and C60 fullerene separately or with C60-Cis-Pt nanocomplex
Experimental groups Tumor weight, g IR, %
Untreated 7.6 ± 0.9
+ Cis-Pt 5.6 ± 0.5* 26.3
+ С60 fullerene 6.2 ± 0.5* 18.4
+ С60-Cis-Pt nanocomplex 4.9 ± 0.4* 35.5
Note: *p < 0.05 as compared to tumor-bearing mice treated with saline.
Tumor morphology after treatment with Cis-Pt, 
C60 fullerene or with C60-Cis-Pt nanocomplex. His-
tological examination of the tumor nodules in untreated 
mice group showed that tissue consisted of a cluster 
of highly polymorphic, atypical cancer cells (Fig. 3, a). 
A large number of cells with large nuclei and nucleoli, 
condensed chromatin grains and light areas of karyo-
plasm were encountered (Fig. 3, b). The giant poly-
morphic cells were also found among carcinoma cells. 
The necrosis foci with perifocal inflammatory infiltrates 
were detected in the stroma of the tumor tissue. Tu-
mors in C60 fullerene treated group showed a decrease 
in signs of polymorphism of carcinoma cells that were 
predominantly round-oval in shape, small in size; also 
cells with segmented nuclei were found (Fig. 3, c). The 
loose arrangement of cells was noted; in some areas, 
the tumor tissue had a cellular structure (Fig. 3, c). In the 
stroma of the tumor tissue in C60-Cis-Pt nanocomplex 
group, the extensive foci of necrosis with the presence 
of a moderately pronounced perifocal inflammatory cell 
response were found (Fig. 3, d).
In separate tumor cells, mitosis was observed, 
which reflects their high proliferative activity (Fig. 4). 
In the Cis-Pt treated group, the microscopic exami-
nation of the tumors showed a decrease in number 
Table 2. Hemogram of LLC-bearing mice treated with either Cis-Pt and C60 fullerene separately or with C60-Cis-Pt nanocomplex (8 mice per group, M ± m, n = 5)
Indices Intact mice Tumor-bearinguntreated
Treatment
С60 fullerene Сis-Pt
С60-Сis-Pt
nanocomplex
Hemoglobin, g/l 107 ± 11 95 ± 7 108 ± 10 75 ± 8§* 100 ± 6#
Hematocrit, % 38 ± 4 30 ± 3§ 31 ± 8 25 ± 4§ 31 ± 8
Erythrocytes, 1012/l 9.23 ± 0.90 5.7 ± 0.48§ 7.5 ± 1.9* 4.6 ± 1.2§* 6.8 ± 0.8*#
Leukocytes, 109/l 7.0 ± 1.2 9.9 ± 0.6§ 8.9 ± 1.4§ 13.0 ± 2.1§* 9.4 ± 1.3#
Lymphocytes, 109/l 4.0 ± 0.3 2.8 ± 0.1§ 3.8 ± 0.2* 1.8 ± 0.1§* 3.0 ± 0.2#
Platelets, 109/l 400 ± 21 282 ± 21§ 360 ± 39* 320 ± 22§ 356 ± 33*
Note: §р < 0.05 as compared to intact mice; *р < 0.05 as compared to tumor-bearing mice treated with saline; #p < 0.05 as compared to tumor-bearing 
mice treated with Cis-Pt.
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of mitotic cells by 65% and an increase in number 
of apoptotic cells by 50% (Fig. 4). In the C60 fullerene 
group, the mitotic index of tumor cells was the same 
as in control group, but the number of apoptotic 
cells was higher than in untreated LLC-bearing mice 
by 50% (Fig. 4). Compared to control, treatment with 
C60-Cis-Pt nanocomplex was found to decrease the 
mitotic index of tumor cells by 78% and increase 
apoptotic index by 75% (Fig. 4).
The action of the C60-Cis-Pt nanocomplex in tu-
mor tissue reduced the number of mitotic cells, but 
increased the number of apoptotic tumor cells, which 
may be one of the mechanisms of its antitumor acti vity. 
It is believed that antitumor efficacy of C60 fullerene 
at complexation with Cis-Pt is not due to the direct kill-
ing of tumor cells but is the result of activation of the 
immune response [47]. Thus, C60 fullerene at complex-
ation with Cis-Pt suppressed Cis-Pt-induced intracel-
lular reactive oxygen and reactive nitrogen species 
production in human peripheral blood phagocytes [48]. 
Also, antineoplastic effect of C60 fullerene has been 
observed by direct toxic effect against human myeloid 
U937 cells, as well as through the modulation of the 
functions of the efector cells of antitumor immunity.
According to literary data, C60 fullerene shows the 
selectivity of accumulation in the body of animals. 
So, C60-PEG and C60(OH)n accumulated more and re-
tained for a longer time in tumor tissues than in normal 
ones [18–20, 49]. C60-ser-PromoFluor-633 conjugate 
after intravenously injection to mouse with liver cancer 
was permeated through the altered vasculature of the 
tumor, evading the reticulo-endothelial system [50]. 
125I-C60(OH)х after intravenously injection accumulated 
in the murine H22 hepatocarcinoma due to enhanced 
permeability and retention effects, and carbon 
nanoparticles were also taken up by the mononuclear 
phagocyte system [19].
Our results revealed C60-Cis-Pt nanocomplex ability 
to prolong a survival of LLC-bearing mice and to pre-
vent tumor- and Cis-Pt-induced hematotoxicity. These 
results need to be investigated further in a number 
of tumor models.
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